ArticleGenome medicine2020
Genetic diversity and characteristics of high-level tigecycline resistance Tet(X) in Acinetobacter species.
Article in Genome medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
51 citing papers in PubMed, 80 citations in OpenAlex.
- Convergent Architecture of thePathogens (Basel, Switzerland) · 2026Article
- The Role of Natural Flavonoid Quercetin in Combating Tet(X3)/Tet(X4)-Positive Bacterial Infections.Microorganisms · 2026Article
- Molecular epidemiology and emergingAntimicrobial agents and chemotherapy · 2026Article
- Molecular epidemiological and genetic variability ofMicrobiology spectrum · 2026Article
- Bovine-DerivedMicroorganisms · 2026Article
- Metagenomic Comparison of Bat Colony Resistomes Across Anthropogenic and Pristine Habitats.Antibiotics (Basel, Switzerland) · 2026Article
- Transcriptomic Analysis of the Impact of theAnimals : an open access journal from MDPI · 2025Article
- Transfer and Fitness of ISMicroorganisms · 2025Article
- Establishment of Specific Multiplex PCR Detection Methods for the PredominantMicroorganisms · 2025Article
- Threat and Control ofFoods (Basel, Switzerland) · 2025Review
- Detection of the Tigecycline Resistance-Mediating tet(Y) Gene in Acinetobacter baumannii Isolates from Intensive Care Unit Patients in Pakistan.The American journal of tropical medicine and hygiene · 2025Article
- Prevalence and characteristics of tigecycline- and carbapenem-resistantAntimicrobial agents and chemotherapy · 2025Article
- Genomic Diversity of theMicroorganisms · 2025Article
- The tetracycline resistome is shaped by selection for specific resistance mechanisms by each antibiotic generation.Nature communications · 2025Article
- Phenotypic and genotypic characterization of clinical carbapenem-resistantMicrobiology spectrum · 2025Article
- PRELP inhibits colorectal cancer progression by suppressing epithelial-mesenchymal transition and angiogenesis via the inactivation of the FGF1/PI3K/AKT pathway.Apoptosis : an international journal on programmed cell death · 2025Article
- Navigating an evolving microbial landscape: emerging antimicrobial resistance trends and precision stewardship in Tianjin tertiary hospitals (2021-2023).Frontiers in cellular and infection microbiology · 2025Article
- Emergence ofCurrent research in microbial sciences · 2025Article
- Convergence of Neuroinflammation, Microbiota, and Parkinson's Disease: Therapeutic Insights and Prospects.International journal of molecular sciences · 2024Review
- Concurrence of Inactivation Enzyme-Encoding GenesFoods (Basel, Switzerland) · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors at 7 institutions in 2 countries.
Funding
Abstract
backgroundThe recent emergence and dissemination of high-level mobile tigecycline resistance Tet(X) challenge the clinical effectiveness of tigecycline, one of the last-resort therapeutic options for complicated infections caused by multidrug-resistant Gram-negative and Gram-positive pathogens. Although tet(X) has been found in various bacterial species, less is known about phylogeographic distribution and phenotypic variance of different genetic variants.
methodsHerein, we conducted a multiregional whole-genome sequencing study of tet(X)-positive Acinetobacter isolates from human, animal, and their surrounding environmental sources in China. The molecular and enzymatic features of tet(X) variants were characterized by clonal expression, microbial degradation, reverse transcription, and gene transfer experiments, while the tet(X) genetic diversity and molecular evolution were explored by comparative genomic and Bayesian evolutionary analyses.
resultsWe identified 193 tet(X)-positive isolates from 3846 samples, with the prevalence ranging from 2.3 to 25.3% in nine provinces in China. The tet(X) was broadly distributed in 12 Acinetobacter species, including six novel species firstly described here. Besides tet(X3) (n = 188) and tet(X4) (n = 5), two tet(X5) variants, tet(X5.2) (n = 36) and tet(X5.3) (n = 4), were also found together with tet(X3) or tet(X4) but without additive effects on tetracyclines. These tet(X)-positive Acinetobacter spp. isolates exhibited 100% resistance rates to tigecycline and tetracycline, as well as high minimum inhibitory concentrations to eravacycline (2-8 μg/mL) and omadacycline (8-16 μg/mL). Genetic analysis revealed that different tet(X) variants shared an analogous ISCR2-mediated transposon structure. The molecular evolutionary analysis indicated that Tet(X) variants likely shared the same common ancestor with the chromosomal monooxygenases that are found in environmental Flavobacteriaceae bacteria, but sequence divergence suggested separation ~ 9900 years ago (7887 BC), presumably associated with the mobilization of tet(X)-like genes through horizontal transfer.
conclusionsFour tet(X) variants were identified in this study, and they were widely distributed in multiple Acinetobacter spp. strains from various ecological niches across China. Our research also highlighted the crucial role of ISCR2 in mobilizing tet(X)-like genes between different Acinetobacter species and explored the evolutionary history of Tet(X)-like monooxygenases. Further studies are needed to evaluate the clinical impact of these mobile tigecycline resistance genes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.